NEW YORK, May 15, 2012 /PRNewswire/ -- 5W Public Relations, a top 25 U.S. PR Agency today announced the addition of IMMUNE Pharmaceuticals to its roster of corporate clients. IMMUNE Pharmaceuticals is an Israel and U.S. based biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing significant unmet medical needs in the treatment of inflammatory diseases and cancer.
5WPR will execute a comprehensive integrated public relations program in order to promote IMMUNE Pharmaceuticals to targeted influential media. Key elements will include media relations, speaker engagement, messaging, web strategies and more.
"5WPR is very excited to be named the PR agency of record for IMMUNE Pharmaceuticals," said Ronn Torossian, President and CEO of 5W Public Relations. "IMMUNE is one of the most innovative and fastest growing Israeli biopharmaceutical companies. We look forward to increasing awareness of IMMUNE and its novel approaches to treating severe diseases and improving quality of life issues," added Ronn Torossian.
IMMUNE Pharmaceuticals has built a robust pipeline of drug candidates. In fall 2012, IMMUNE will start phase II clinical trials in Crohn's Disease and Ulcerative Colitis with its lead drug, Bertilimumab. IMMUNE's NanomAbs, developed in partnership with the Hebrew University of Jerusalem, are the next generation Antibody Drug Conjugates, which specifically targets tumor cells, thereby improving efficacy and safety of cancer treatments. With annual sector sales reaching over $50 billion, monoclonal antibodies are one of the most attractive pharmaceutical markets.
SOURCE 5W Public Relations